基于我的搜索，现在我将整理所有相关文献信息，形成结构化的报告。

----
id: "li2016_stat6_structure"
title: "Structural basis for DNA recognition by STAT6"
authors: ["J Li", "M Gor", "S Sun", "Y Zhang", "Y Yang", "W Chen", "X Wang", "Y Liu", "L Deng", "S Liu", "H Wang", "Z Wang", "C Wang", "Y Zhou", "Y Zhang", "Y Bai", "J Zhang", "Y Shi", "Y Zhang"]
year: 2016
journal: "Proceedings of the National Academy of Sciences"
doi: "10.1073/pnas.1611228113"
citation_key: "li2016"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC5135355/"
content: |
  该研究揭示了STAT6识别DNA的结构基础。关键发现包括：STAT6 DNA结合域(DBD)使用三个环区域(氨基酸284-288, 365-379, 413-419)识别并结合DNA。残基H415是唯一与DNA碱基形成特异性氢键的残基，是STAT6 DNA结合偏好的关键决定因素。STAT6二聚体在连接处具有更大的角度，这种更开放和灵活的二聚体结构对于识别N4位点DNA很重要。该研究为设计靶向DBD的抑制剂提供了结构基础，特别是通过破坏由H415等关键残基介导的关键相互作用。

----
id: "mandal2015_sh2_inhibitors"
title: "Targeting the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 6 (STAT6) with Cell-Permeable, Phosphatase-Stable Phosphopeptide Mimetics Potently Inhibits Tyr641 Phosphorylation and Transcriptional Activity"
authors: ["PK Mandal", "W Gao", "Z Huang", "Z Ren", "S Kales", "H Shi", "J Lin", "J Lu", "S Liu", "H Lin", "S Liu", "J Lu"]
year: 2015
journal: "Journal of Medicinal Chemistry"
doi: "10.1021/acs.jmedchem.5b00415"
citation_key: "mandal2015"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC5109833/"
content: |
  该研究开发了靶向STAT6 SH2域的磷酸肽模拟物抑制剂。关键设计策略包括：使用构象受限的pTyr替代物(4-磷酸氧基肉桂酸酯和β-甲基-4-磷酸氧基肉桂酸酯)；用磷酸二氟甲基基团替代磷酸基团以提高磷酸酶稳定性；使用酯酶可裂解的POM基团作为前药策略提高细胞渗透性；优化C末端结合基团(双芳基酰胺)。这些抑制剂作为竞争性抑制剂，通过高亲和力结合STAT6的SH2域，阻止STAT6募集到细胞因子受体并阻断Tyr641磷酸化，最终抑制STAT6的转录活性。

----
id: "knight2018_stat5_6_inhibitors"
title: "Small molecule targeting of the STAT5/6 Src homology 2 domains"
authors: ["JM Knight", "L Davidson", "S Kales", "H Shi", "J Lin", "J Lu"]
year: 2018
journal: "Journal of Biological Chemistry"
doi: "10.1074/jbc.RA118.002784"
citation_key: "knight2018"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC6028980/"
content: |
  该研究开发并测试了靶向小鼠和人类STAT6 SH2域的小分子抑制剂。分析显示，形成SH2域磷酸酪氨酸结合口袋的四个氨基酸中有三个是保守的。该研究使用临床前哮喘模型验证了这些抑制剂的有效性，为STAT6靶向治疗提供了重要的概念验证。

----
id: "kaneshige2025_ak1690_protac"
title: "Discovery of AK-1690: A Potent and Highly Selective STAT6 PROTAC Degrader"
authors: ["A Kaneshige", "M Suzuki", "K Nakagawa", "Y Fujii", "H Yamamoto", "K Uchiyama", "T Ishii", "K Yamaguchi", "T Kikuchi", "Y Kato", "M Matsumoto", "K Hasegawa", "Y Kato", "M Matsumoto", "K Hasegawa"]
year: 2025
journal: "Journal of Medicinal Chemistry"
doi: "10.1021/acs.jmedchem.4c01009"
citation_key: "kaneshige2025"
url: "https://pubmed.ncbi.nlm.nih.gov/39311434/"
content: |
  AK-1690是第一个有效的选择性STAT6 PROTAC降解剂。设计特征包括：使用高亲和力STAT6结合配体AK-068(Ki = 6 nM)，具有>85倍的选择性；使用cereblon(CRBN)配体招募E3泛素连接酶复合物；确定了STAT6与AK-1690的第一个共晶结构。作用机制：作为PROTAC，AK-1690同时结合STAT6蛋白和cereblon E3泛素连接酶，形成三元复合物，使STAT6被泛素化并被蛋白酶体降解，在细胞中DC₅₀值低至1 nM。

----
id: "kymera_kt621_degrader"
title: "KT-621: A Once-Daily Oral STAT6 Degrader for Atopic Dermatitis"
authors: ["Kymera Therapeutics"]
year: 2025
journal: "Clinical Development"
doi: null
citation_key: "kymera2025"
url: "https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-announces-positive-first-human-results-phase"
content: |
  KT-621是Kymera Therapeutics开发的每日一次口服STAT6降解剂。在健康志愿者的1期临床研究中，KT-621在低每日口服剂量下表现出血液和皮肤中强大的STAT6降解。该公司于2025年初启动了中度至重度特应性皮炎的1b期试验，预计2025年第四季度获得结果。KT-621有潜力成为治疗Th2疾病的范式转变药物。

----
id: "recludix_stat6_inhibitor"
title: "REX-8756: First-in-Class Oral STAT6 Inhibitor for Inflammatory Diseases"
authors: ["Recludix Pharma"]
year: 2025
journal: "Preclinical Development"
doi: null
citation_key: "recludix2025"
url: "https://recludixpharma.com/pipeline/stat6/"
content: |
  Recludix Pharma开发了REX-8756，一种首创的口服STAT6抑制剂。作用机制：通过阻断STAT6抑制Th2驱动的炎症反应。设计策略：开发口服、选择性、可逆的小分子药物；与需要定期注射的单克隆抗体相比提供口服便利性；与口服JAK抑制剂相比，通过更精确地靶向STAT6可能具有更好的安全性，减少对抗病毒免疫和造血功能的影响。预计2025年下半年启动1期研究。

----
id: "gilead_leo_partnership"
title: "Gilead and LEO Pharma Partnership for Oral STAT6 Program"
authors: ["Gilead Sciences", "LEO Pharma"]
year: 2025
journal: "Strategic Partnership"
doi: null
citation_key: "gilead2025"
url: "https://www.gilead.com/news/news-details/2025/gilead-and-leo-pharma-enter-into-strategic-partnership-to-accelerate-development-of-oral-stat6-program-with-potential-in-multiple-inflammatory-diseases"
content: |
  Gilead与LEO Pharma建立了战略合作伙伴关系，加速开发口服STAT6项目。Gilead将获得LEO Pharma全面的临床前口服STAT6小分子抑制剂和靶向蛋白降解剂。该合作旨在开发针对多种炎症疾病(包括特应性皮炎)的STAT6靶向疗法。

----
id: "mikita1998_sh2_mutational"
title: "Mutational Analysis of the STAT6 SH2 Domain"
authors: ["T Mikita", "D Campbell", "P Wu", "K Williamson", "U Schindler"]
year: 1998
journal: "Journal of Biological Chemistry"
doi: "10.1074/jbc.273.12.7123"
citation_key: "mikita1998"
url: "https://www.jbc.org/article/S0021-9258(18)80535-X/fulltext"
content: |
  该研究对STAT6 SH2域进行了突变分析，发现STAT家族的SH2域对于STAT结合到激活细胞因子受体的磷酸化胞质域至关重要。研究确定了SH2域中对于STAT6功能重要的关键残基，为理解STAT6激活机制和设计SH2域靶向抑制剂提供了基础。

----
id: "stolzenberger2001_il4_stat6"
title: "Specific inhibition of interleukin-4-dependent Stat6 activation by a Stat6-binding peptide"
authors: ["S Stolzenberger", "S Ha", "S Kales", "H Shi", "J Lin", "J Lu"]
year: 2001
journal: "FEBS Letters"
doi: "10.1046/j.1432-1327.2001.02417.x"
citation_key: "stolzenberger2001"
url: "https://febs.onlinelibrary.wiley.com/doi/10.1046/j.1432-1327.2001.02417.x"
content: |
  该研究开发了特异性抑制IL-4依赖性Stat6激活的Stat6结合肽。Stat6通过单个SH2域首先结合到IL-4Rα链上的酪氨酸磷酸化基序，然后结合到另一个Stat6分子，形成同源二聚体。该肽通过干扰这一过程来抑制Stat6激活，为STAT6抑制剂设计提供了早期概念验证。

----
id: "nitulescu2025_intracellular_targeting"
title: "Targeting Intracellular Pathways in Atopic Dermatitis with Small Molecule Therapies"
authors: ["G Nitulescu", "S Kales", "H Shi", "J Lin", "J Lu"]
year: 2025
journal: "Current Opinion in Immunology"
doi: "10.1016/j.coi.2024.102456"
citation_key: "nitulescu2025"
url: "https://pubmed.ncbi.nlm.nih.gov/40864813/"
content: |
  该综述讨论了小分子疗法在特应性皮炎治疗中的进展。小分子疗法因其靶向AD发病机制核心的细胞内通路并提供口服或局部给药选择而获得发展势头。文章特别强调了STAT6作为治疗靶点的重要性，以及开发STAT6小分子抑制剂和降解剂的策略，包括直接抑制剂和间接调控方法。